Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the second quarter of fiscal 2025 were $2.43, up 29.2% year over year. The metric beat the Zacks Consensus Estimate by 5.6%. The ...

ResMed (NYSE: RMD) + stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 results. The results, out after market close yesterday ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.

MMSI Merit Medical Systems, Inc.